Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

Blood

Volumn 115, Issue 6, 2010, Pages 1145-1155

  Keymeulen, Bart ^a   Candon, Sophie ^b,c   Fafi Kremer, Samira ^d   Ziegler, Anette ^e   Leruez Ville, Marianne ^b,c   Mathieu, Chantal ^f   Vandemeulebroucke, Evy ^a   Walter, Markus ^e   Crenier, Laurent ^g   Thervet, Eric ^b,c   Legendre, Christophe ^b,c   Pierard, Denis ^a   Hale, Geoff ^h   Waldmann, Herman ^h   Bach, Jean François ^b,c   Seigneurin, Jean Marie ⁱ   Pipeleers, Daniel ^a   Chatenoud, Lucienne ^b,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e Klinikum Schwabing   (Germany)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CHAGLYCD3 ANTIBODY; DACLIZUMAB; MONOCLONAL ANTIBODY CD3; PLACEBO; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CD3 ANTIGEN; MONOCLONAL ANTIBODY; VIRUS DNA;

ARTICLE; B LYMPHOCYTE ACTIVATION; CERVICAL LYMPHADENOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; FEVER; FLU LIKE SYNDROME; GRAFT RECIPIENT; HUMAN; HYPERTHERMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ALLOGRAFT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SORE THROAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; B LYMPHOCYTE; CYTOLOGY; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; GENETICS; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PALATINE TONSIL; PHENOTYPE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; PALATINE TONSIL; PHENOTYPE; PLACEBOS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VIRAL LOAD; VIRUS ACTIVATION;

EID: 77949513969     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-204875     Document Type: Article

References (50)

1. Fafi-Kremer S, Morand P, Brion JP, et al. Longterm shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis. 2005;191(6):985-989. (Pubitemid 40349816)
2. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89(1):98-103.
3. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97(5):1165-1171. (Pubitemid 32183736)
4. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364-4369.
5. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation. 2004;77(1):76-84.
6. Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M. Human immunodeficiency virus-ssociated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol. 1993;11(9):1674-1681.
7. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-2344.
8. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598-2608. (Pubitemid 41007846)
9. Chatenoud L, Primo J, Bach JF. CD3 antibody-nduced dominant self tolerance in overtly diabetic NOD mice. J Immunol. 1997;158(6):2947-2954. (Pubitemid 127470558)
10. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91(1):123-127. (Pubitemid 24018655)
11. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3(2):123-132. (Pubitemid 37328690)
12. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-1698. (Pubitemid 34547482)
13. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol. 1993;23(2):403-411. (Pubitemid 23075070)
14. Keymeulen B, Gillard P, Mathieu C, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A. 2006;103(46):17444-17449.
15. Brengel-Pesce K, Morand P, Schmuck A, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol. 2002;66(3):360-369. (Pubitemid 34111777)
16. Fafi-Kremer S, Morand P, Barranger C, et al. Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms. J Mol Diagn. 2008;10(1):78-84.
17. Ryan JL, Fan H, Swinnen LJ, et al. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol. 2004;13(2):61-68. (Pubitemid 38668140)
18. Ballout M, Germi R, Fafi-Kremer S, et al. Realtime quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. J Virol Methods. 2007;143(1):38-44. (Pubitemid 46802823)
19. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T-cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195(7):893-905.
20. + T-cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol. 2001;167(4):2019-2029.
21. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Is EBV persistence in vivo a model for B-cell homeostasis? Immunity. 1996;5(2):173-179. (Pubitemid 26301093)
22. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol. 2004;78(10):5194-5204. (Pubitemid 38581471)
23. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75-82.
24. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol. 2005;15(3):149-156.
25. Mattila PS, Tarkkanen J. Differentiation of T lymphocytes in the human adenoid as measured by the expression of CD45 isoforms. Scand J Immunol. 1998;48(1):59-64. (Pubitemid 28329153)
26. Croft NP, Shannon-Lowe C, Bell AI, et al. Stagespecific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 2009;5(6):e1000490.
27. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK-cell killing. J Virol. 2007;81(2):474-482. (Pubitemid 46067874)
28. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008;111(3):1420-1427.
29. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763-1769. (Pubitemid 40770766)
30. + Tregs. J Clin Invest. 2005;115(10):2904-2913.
31. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol. 1982;12(11):979-982.
32. Chatenoud L, Bach JF. Antigenic modulation - a major mechanism of antibody action. Immunol Today. 1984;5(1):20-25.
33. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol. 1986;137(3):830-838.
34. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation. 1986;41(6):730-733.
35. Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113(11):2442-2450.
36. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47(4):606-608.
37. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49(4):697-702.
38. Debets JM, Leunissen KM, van Hooff HJ, van der Linden CJ, Buurman WA. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation. 1989;47(3):487-492.
39. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A. 2002;99(1):437-442. (Pubitemid 34060379)
40. Fu Z, Cannon MJ. Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol. 2000;74(14):6675-6679. (Pubitemid 30429839)
41. Konforte D, Paige CJ. Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein-Barr virus infected B cells. Virus Res. 2009;144(1-2):339-343.
42. Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis. 2002;186(3):405-409.
43. Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS. 2002;16(7):993-1001.
44. Aalto SM, Linnavuori K, Peltola H, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol. 1998;56(3):186-191. (Pubitemid 28458083)
45. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol. 2004;172(2):1287-1294. (Pubitemid 38113792)
46. De Milito A. B lymphocyte dysfunctions in HIV infection. Curr HIV Res. 2004;2(1):11-21.
47. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881-1888.
48. Aukrust P, Liabakk NB, Mü ller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169(2):420-424. (Pubitemid 24045606)
49. Piriou ER, van Dort K, Nanlohy NM, Miedema F, van Oers MH, van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol. 2004;172(11):6931-6937. (Pubitemid 38669132)
50. Piriou E, van Dort K, Otto S, van Oers MH, van Baarle D. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection. Clin Infect Dis. 2008;46(2):313-316.